85 related articles for article (PubMed ID: 20542209)
1. In vitro synergistic/additive activity of levofloxacin with meropenem against Stenotrophomonas maltophilia.
Pankey GA; Ashcraft DS
Diagn Microbiol Infect Dis; 2010 Jul; 67(3):297-300. PubMed ID: 20542209
[TBL] [Abstract][Full Text] [Related]
2. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay.
Pankey GA; Ashcraft DS
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):228-32. PubMed ID: 19150711
[TBL] [Abstract][Full Text] [Related]
3. Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae.
Pankey GA; Ashcraft DS
Diagn Microbiol Infect Dis; 2011 Aug; 70(4):561-4. PubMed ID: 21767715
[TBL] [Abstract][Full Text] [Related]
4. In vitro bactericidal activity of the N-terminal fragment of the frog peptide esculentin-1b (Esc 1-18) in combination with conventional antibiotics against Stenotrophomonas maltophilia.
Maisetta G; Mangoni ML; Esin S; Pichierri G; Capria AL; Brancatisano FL; Di Luca M; Barnini S; Barra D; Campa M; Batoni G
Peptides; 2009 Sep; 30(9):1622-6. PubMed ID: 19520127
[TBL] [Abstract][Full Text] [Related]
5. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates.
Bonfiglio G; Cascone C; Azzarelli C; Cafiso V; Marchetti F; Stefani S
J Antimicrob Chemother; 2000 Jan; 45(1):115-7. PubMed ID: 10629022
[TBL] [Abstract][Full Text] [Related]
6. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections.
Passerini de Rossi B; García C; Calenda M; Vay C; Franco M
Int J Antimicrob Agents; 2009 Sep; 34(3):260-4. PubMed ID: 19362452
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
Galles AC; Jones RN; Sader HS
J Chemother; 2008 Feb; 20(1):38-42. PubMed ID: 18343741
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia.
Insa R; Cercenado E; Goyanes MJ; Morente A; Bouza E
J Antimicrob Chemother; 2007 Mar; 59(3):583-5. PubMed ID: 17213264
[No Abstract] [Full Text] [Related]
9. Antibacterial effects of theaflavin and synergy with epicatechin against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia.
Betts JW; Kelly SM; Haswell SJ
Int J Antimicrob Agents; 2011 Nov; 38(5):421-5. PubMed ID: 21885260
[TBL] [Abstract][Full Text] [Related]
10. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii.
Kiffer CR; Sampaio JL; Sinto S; Oplustil CP; Koga PC; Arruda AC; Turner PJ; Mendes C
Diagn Microbiol Infect Dis; 2005 Aug; 52(4):317-22. PubMed ID: 15936166
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods.
Nicodemo AC; Araujo MR; Ruiz AS; Gales AC
J Antimicrob Chemother; 2004 Apr; 53(4):604-8. PubMed ID: 14973153
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Wexler HM; Engel AE; Glass D; Li C
Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
[TBL] [Abstract][Full Text] [Related]
13. Comparison of serum bactericidal activity of ceftazidime, ciprofloxacin and meropenem against Stenotrophomonas maltophilia.
Lemmen SW; Häfner H; Reinert RR; Zolldann D; Kümmerer K; Lütticken R
J Antimicrob Chemother; 2001 Jan; 47(1):118-20. PubMed ID: 11152445
[No Abstract] [Full Text] [Related]
14. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Apr; 42(4):953-5. PubMed ID: 9559819
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia.
Giacometti A; Cirioni O; Del Prete MS; Barchiesi F; Fortuna M; Drenaggi D; Scalise G
Antimicrob Agents Chemother; 2000 Jun; 44(6):1716-9. PubMed ID: 10817738
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates.
Church D; Lloyd T; Peirano G; Pitout J
Scand J Infect Dis; 2013 Apr; 45(4):265-70. PubMed ID: 23113657
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations.
Hu LF; Gao LP; Ye Y; Chen X; Zhou XT; Yang HF; Liiu YY; Mei Q; Li JB
J Chemother; 2014 Oct; 26(5):282-6. PubMed ID: 24588423
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) against clinical isolates of Stenotrophomonas maltophilia.
Gordon NC; Wareham DW
Int J Antimicrob Agents; 2010 Aug; 36(2):129-31. PubMed ID: 20472404
[TBL] [Abstract][Full Text] [Related]
19. Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia.
Alonso A; Martinez JL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1879-81. PubMed ID: 11353642
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies.
Venditti M; Monaco M; Micozzi A; Tarasi A; Friedrich A; Martino P
Clin Microbiol Infect; 2001 Jan; 7(1):37-9. PubMed ID: 11284945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
